We’re excited to announce that from December 13-16, Bruker Cellular Analysis will be an exhibitor at this year’s Antibody Engineering & Therapeutics Conference in San Diego. This premier event is dedicated to showcasing the latest advancements in antibody engineering, design, and selection. With a focus on diverse topics such as Neurodegenerative Diseases, Tumor Microenvironment in […]
Cellular Analysis Blog
Explore Antibody Discovery Articles
Latest
Explore Cutting-Edge Antibody Discovery with Bruker Cellular Analysis at the Antibody Engineering & Therapeutics Conference
Unveiling the Future of Protein and Antibody Research: The PEGS International Conference
The Protein & Antibody Engineering Summit (PEGS) International Conference, set to take place from November 14-16th at the Lisbon Congress Center in Lisbon, Portugal, is the largest protein & antibody engineering event in Europe, which has been described as “the best biologics technology meeting in Europe.” The team from Bruker Cellular Analysis will be at […]
Published in Antibody Therapeutics: Alpaca Single B Cell Interrogation and Heavy-Chain-Only Antibody Discovery on the Beacon® Platform
Researchers have used Bruker Cellular Analysis’ Optofluidic technology to establish the fastest high-resolution workflow for the discovery and engineering of VHH antibodies yet. Scientists developed a novel application leveraging Bruker’s optofluidic Beacon® platform to detect IgG2/3 antibodies from activated memory B cells derived from alpaca peripheral blood samples. B cells secreting PSMA-specific antibodies were recovered […]
Upcoming Webinar: Accelerating Antibody Discovery for Difficult Targets
Scientists often use classical immunization strategies and hybridoma technologies to generate antibodies. However, when producing antibodies against poorly immunogenic targets, such as membrane proteins with short extracellular domains, these approaches achieve limited antibody diversity, making it difficult for scientists to select good candidates for pharmaceutical development. Innovative approaches that combine RNA immunization and single cell […]
Accelerate Antibody Discovery with the Opto® B Discovery Workflow on the Beacon® Platform
Unlock the future of antibody discovery with Opto® B Discovery on the Beacon® platform. This cutting-edge technology streamlines the process, drastically reducing time and cost. This state-of-the-art workflow leverages up to 4 optofluidic chips, characterizing single B cells quickly and efficiently. With the Opto® B Discovery workflow, the Beacon system can significantly speed up your […]
Upcoming Webinar 9/14/23: Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization
Biotherapeutics comprise a large portion of the treatment options for a wide range of conditions and account for almost half of drugs approvals in 2022. However, the pace of new biologic development has not grown in recent years in part because of the increasing complexity of drug targets and desired performance of these drugs. To […]
Put Your Best Cells Forward: Overcoming the Challenges of Ion Channel Antibody Discovery
With an estimated $12 billion in worldwide sales1, ion channel antibodies are the third best-selling group of prescribed drugs and a huge potential growth area. But the inefficiencies of traditional antibody discovery processes can oftentimes block the road to market approval in early-stage development. Methods such as hybridoma and B cell sequencing comprise multiple manual time-consuming […]
- « Previous
- 1
- 2
Unlock the Phenome